Oculis: Strengthening Clinical and Regulatory Momentum Supports Buy Rating and $42 Target
I'm PortAI, I can summarize articles.
H.C. Wainwright's Yi Chen maintains a Buy rating on Oculis Holding with a $42 price target, citing a strong clinical and regulatory outlook. The FDA's Breakthrough Therapy designation for privosegtor in optic neuritis highlights its market potential. Oculis is advancing its PIONEER-1 trial and plans further studies. Additionally, OCS-01 is in Phase 3 trials for diabetic macular edema, with results expected in 2Q26. Chen believes the favorable risk-reward profile justifies the Buy rating and target price.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments